Sunderrajan S, Reams G, Bauer J H
Am Heart J. 1987 Aug;114(2):383-8. doi: 10.1016/0002-8703(87)90507-2.
Eighteen hypertensive patients underwent short-term (8 weeks) and long-term (6 months) assessment of renal function and body fluid composition following diltiazem monotherapy (240 to 480 mg/day). Diltiazem monotherapy effectively lowered blood pressure in 60% of patients at 8 weeks. In 12 of the 18 patients continued on diltiazem monotherapy for 6 months, good control of blood pressure was sustained. Glomerular filtration rate, effective renal plasma flow, filtration fraction, and renal vascular resistance were unchanged throughout the protocol period. In individuals with pretreatment glomerular filtration rates less than or equal to 80 ml/min/1.73m2, diltiazem monotherapy showed both short-term and long-term improvement in glomerular filtration rate (62%) and effective renal plasma flow (34%). Filtration fraction was unchanged, suggesting that the changes in glomerular filtration rate might be related to the attenuated intrarenal effects of angiotensin II and/or norepinephrine. No long-term effect was seen on salt and water excretion or body fluid composition.
18例高血压患者在接受地尔硫䓬单药治疗(240至480毫克/天)后,进行了短期(8周)和长期(6个月)的肾功能及体液成分评估。地尔硫䓬单药治疗在8周时有效降低了60%患者的血压。18例患者中有12例继续接受地尔硫䓬单药治疗6个月,血压得到持续良好控制。在整个试验期间,肾小球滤过率、有效肾血浆流量、滤过分数和肾血管阻力均未改变。在治疗前肾小球滤过率小于或等于80毫升/分钟/1.73平方米的个体中,地尔硫䓬单药治疗在短期和长期均显示出肾小球滤过率(62%)和有效肾血浆流量(34%)的改善。滤过分数未改变,提示肾小球滤过率的变化可能与血管紧张素II和/或去甲肾上腺素的肾内作用减弱有关。对盐和水排泄或体液成分未见长期影响。